Personalis Inc (Nasdaq: PSNL), a provider of advanced genomics for precision oncology, on Tuesday announced validation of its NeXT Personal test, an ultra-sensitive circulating tumour DNA (ctDNA) assay designed for early cancer recurrence detection and treatment response monitoring.

The study, published in Oncotarget, evaluated NeXT Personal's analytical sensitivity and specificity across nine cancer types, demonstrating a detection threshold of 1.67 parts per million (PPM) of ctDNA with 100% measured analytical specificity.

Initial findings presented at the 2023 European Society for Medical Oncology (ESMO) Congress indicated improved detection rates, particularly in early-stage lung cancer, showing the assay's potential clinical benefit in early disease management.

NeXT Personal leverages whole genome sequencing (WGS) and advanced noise suppression to identify a patient's unique tumour genetic signature, aiding in personalised cancer management from biopsy through to treatment.